Form 4: Vertex Pharma EVP Sells Shares for Tax

Vertex Pharmaceuticals' EVP and CMO, Carmen Bozic, disposed of 2,145 shares of common stock to cover tax liabilities at a price of $468.41 per share.

Summary

• Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc. (VRTX), reported a transaction involving company common stock.
• On February 10, 2026, Ms. Bozic disposed of 2,145 shares of common stock.
• The disposition was made at a price of $468.41 per share.
• Following this transaction, Ms. Bozic beneficially owns 41,857 shares of Vertex Pharmaceuticals common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.
• The transaction code "F" indicates a disposition to the issuer in payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise, or vesting of a security.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine, non-discretionary disposition of shares by an executive to satisfy tax obligations, which is a common practice in executive compensation.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, which demonstrates pre-planned trading activity and adherence to insider trading regulations.

Negatives

• No specific negatives are indicated by a routine tax-related disposition.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that dispositions of shares by executives to cover tax liabilities, often associated with the vesting of equity awards, are a common and routine occurrence in publicly traded companies. The use of a Rule 10b5-1 plan indicates a pre-scheduled transaction, which is a standard practice for managing insider stock sales transparently.

Comparison to Industry Standards

• This transaction is a routine tax-related disposition, common across all industries for executives receiving equity compensation. It does not provide specific financial results for comparison to industry benchmarks or competitor performance.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine tax-related disposition and not a discretionary sale indicating a change in management's outlook.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider transaction.

Key Dates

Recommendation

A routine disposition of shares by an executive to cover tax liabilities, especially when conducted under a Rule 10b5-1 plan, is a common and expected event. It does not reflect a change in the company's fundamental prospects or the executive's confidence in the company, therefore, it does not warrant a change in investment recommendation.

Keywords

Vertex Pharmaceuticals, VRTX, Insider Trading, Form 4, Executive Stock Sale, Carmen Bozic, Tax Liability, Rule 10b5-1